These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22191778)

  • 1. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.
    Navarro G; Sawant RR; Biswas S; Essex S; Tros de Ilarduya C; Torchilin VP
    Nanomedicine (Lond); 2012 Jan; 7(1):65-78. PubMed ID: 22191778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
    Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
    J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.
    Essex S; Navarro G; Sabhachandani P; Chordia A; Trivedi M; Movassaghian S; Torchilin VP
    Gene Ther; 2015 Mar; 22(3):257-266. PubMed ID: 25354685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells.
    Lu S; Morris VB; Labhasetwar V
    J Pharmacol Exp Ther; 2019 Sep; 370(3):902-910. PubMed ID: 30940690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.
    Kobayashi E; Iyer AK; Hornicek FJ; Amiji MM; Duan Z
    Clin Orthop Relat Res; 2013 Mar; 471(3):915-25. PubMed ID: 23011844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells.
    Lin G; Zhu W; Yang L; Wu J; Lin B; Xu Y; Cheng Z; Xia C; Gong Q; Song B; Ai H
    Biomaterials; 2014 Nov; 35(35):9495-507. PubMed ID: 25155545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
    Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
    Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
    [No Abstract]   [Full Text] [Related]  

  • 8. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.
    Meng H; Liong M; Xia T; Li Z; Ji Z; Zink JI; Nel AE
    ACS Nano; 2010 Aug; 4(8):4539-50. PubMed ID: 20731437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
    Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
    ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
    Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
    Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.
    Patil YB; Swaminathan SK; Sadhukha T; Ma L; Panyam J
    Biomaterials; 2010 Jan; 31(2):358-65. PubMed ID: 19800114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.
    Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
    Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression.
    Huang HY; Kuo WT; Chou MJ; Huang YY
    J Biomed Mater Res A; 2011 Jun; 97(3):330-8. PubMed ID: 21465641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
    Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
    Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
    Dönmez Y; Gündüz U
    Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas.
    Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK
    Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.